Qiagen N.V. (QGEN) — 6-K Filings

6-K Filings (22)

• 6-K Filing — Dec 22, 2025
• 6-K Filing — Nov 6, 2025
• QIAGEN N.V. Files Q3 2025 Report (6-K) — Sep 2, 2025 Risk: low
  QIAGEN N.V. filed a Form 6-K on September 2, 2025, for the quarterly period ended August 31, 2025. The filing is a report of a foreign private issuer and includ
• QIAGEN N.V. Files Q2 2025 6-K Report — Aug 21, 2025 Risk: low
  QIAGEN N.V. filed a Form 6-K for the quarterly period ended June 30, 2025. The filing, submitted on August 21, 2025, is a report of a foreign private issuer. Th
• QIAGEN N.V. Files Q2 2025 6-K Report — Aug 7, 2025 Risk: low
  QIAGEN N.V. filed a Form 6-K on August 7, 2025, reporting on its quarterly period ended June 30, 2025. The filing is a report of a foreign private issuer and in
• QIAGEN Appoints Stephen H. Rusckowski as Chairman — Jun 30, 2025 Risk: low
  QIAGEN N.V. announced on June 26, 2025, that its Supervisory Board has elected Stephen H. Rusckowski as Chairman. This decision follows the company's Annual Gen
• QIAGEN N.V. Files Q1 2025 6-K Report — May 13, 2025 Risk: low
  QIAGEN N.V. filed a Form 6-K for the quarterly period ended March 31, 2025. The report is for a foreign private issuer and includes information on other matters
• QIAGEN N.V. Files Q1 2025 6-K Report — May 9, 2025 Risk: low
  QIAGEN N.V. filed a Form 6-K for the quarterly period ended March 31, 2025. This report is for a foreign private issuer and includes information under 'Other In
• QIAGEN Raises 2025 EPS Outlook on Strong Q1 — Apr 9, 2025 Risk: low
  QIAGEN N.V. announced preliminary Q1 2025 results on April 6, 2025, and raised its full-year 2025 adjusted earnings per share (EPS) outlook. The company provide
• QIAGEN N.V. Files 6-K for Q4 2024 Period — Feb 7, 2025 Risk: low
  QIAGEN N.V. filed a Form 6-K on February 7, 2025, reporting on its quarterly period ended December 31, 2024. The filing includes information about the company's
• QIAGEN Completes Synthetic Share Repurchase Plan — Jan 16, 2025 Risk: low
  On January 16, 2025, QIAGEN N.V. announced the completion of a synthetic share repurchase plan. This plan involves a direct capital repayment combined with a re
• QIAGEN to Return $300M to Shareholders via Synthetic Repurchase — Jan 13, 2025 Risk: low
  On January 12, 2025, QIAGEN N.V. announced plans to return approximately $300 million to its shareholders. This will be achieved through a synthetic share repur
• QIAGEN N.V. Reports Change in Certifying Accountant — Nov 8, 2024 Risk: low
  QIAGEN N.V. filed a Form 6-K on November 8, 2024, reporting changes related to its certifying accountant for the period ending October 31, 2024. The filing indi
• QIAGEN Finalizes Convertible Bond Offering Terms — Sep 4, 2024 Risk: medium
  On September 3, 2024, QIAGEN N.V. announced the final terms for its offering of new senior, unsecured net share settled convertible bonds. The company is offeri
• QIAGEN Proposes $450M Convertible Bond Offering — Sep 3, 2024 Risk: medium
  On September 3, 2024, QIAGEN N.V. announced a proposed offering of US$450.0 million in senior, unsecured net share settled convertible bonds. This offering is b
• QIAGEN N.V. Files 6-K on Annual Shareholder Meeting — Aug 2, 2024 Risk: low
  QIAGEN N.V. filed a Form 6-K on August 2, 2024, reporting on its Annual General Meeting of Shareholders held on June 21, 2024. The filing includes related mater
• QIAGEN N.V. Holds Capital Markets Day — Jun 24, 2024 Risk: low
  QIAGEN N.V. held a Capital Markets Day event in New York, New York on June 17, 2024. The company furnished a press release and presentation materials related to
• QIAGEN Discontinues NeuMoDx Molecular Systems — Jun 6, 2024 Risk: medium
  On June 6, 2024, QIAGEN N.V. announced its decision to discontinue the NeuMoDx 96 and 288 Molecular Systems. This decision was detailed in a press release furni
• QIAGEN N.V. Files Q1 2024 6-K Report — May 1, 2024 Risk: low
  QIAGEN N.V. filed a Form 6-K for the quarterly period ended March 31, 2024. The filing is a report of a foreign private issuer and includes information on other
• QIAGEN Files 6-K, Reports Unaudited Q4 & FY 2023 Results — Feb 8, 2024 Risk: low
  QIAGEN N.V. (NYSE: QGEN) filed a 6-K on February 8, 2024, to announce its unaudited financial results for the fourth quarter and full year ended December 31, 20
• QIAGEN Details $300M Synthetic Share Buyback Plan — Jan 23, 2024
  QIAGEN N.V. (NYSE: QGEN) announced on January 18, 2024, the details for completing a synthetic share repurchase plan of up to approximately $300 million. This p
• QIAGEN to Return $300M to Shareholders via Synthetic Buyback — Jan 8, 2024
  QIAGEN N.V. (NYSE: QGEN) announced on January 7, 2024, plans to return approximately $300 million to shareholders through a synthetic share repurchase, combinin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX